Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice

Fig. 3

Dynamic GluCEST and GABACEST evaluation of 3xTg AD mice treated with riluzole. (A, B) GluCEST and GABACEST images of the whole brain, hippocampus, and cortex in AD_R, AD_C, C57_R, and C57_C groups at baseline, 6, 12 and 20 weeks post-treatment. (C, D) Quantitative analysis of GluCEST and GABACEST signals in the hippocampus and cortex over time. (E, F) Comparative analysis of GluCEST and GABACEST signals in the hippocampus and cortex across four groups at 20 weeks post treatment. Data were presented as mean ± SD. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193